A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction

Suzanne J. F. Kaptein, Olivia Goethals, Dominik Kiemel, +21

Nature

Ns3–ns4b InteractionImmunologyAntiviral Drug DevelopmentVirologyAntiviral Drug +2

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors

Olivia Goethals, R. Clayton, Marcia Van Ginderen, +13

Journal of Virology

Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates

Olivia Goethals, Suzanne J. F. Kaptein, Bart Kesteleyn, +41

Nature

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

Olivia Goethals, Ann Vos, Marcia Van Ginderen, +5

Virology

Minor Fold ChangesPrimary MutationsSecond-generation Resistance ProfilesMedicineImmunology +10

Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery

Franck Touret, Cécile Baronti, Olivia Goethals, +3

Antiviral Research

EngineeringDengue Inhibitory CompoundsArbovirusVector Borne DiseaseAvailable Genotypes +21

Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes

R. Clayton, Åsa Öhagen, François Nicol, +14

Antiviral Research

Protease InhibitorHuman RetrovirusImmunologyAntiviral Drug DevelopmentMolecular Biology +7

Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation

Dominik Kiemel, Ann-Sophie Helene Kroell, Solène Denolly, +12

Nature Communications

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

Olivia Goethals, Marcia Van Ginderen, Ann Vos, +10

Antiviral Research

Codon 148Human RetrovirusPathogenesisImmunologyAntiviral Drug Development +8

Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor

Bart Kesteleyn, Jean‐François Bonfanti, Dorothée Bardiot, +18

Journal of Medicinal Chemistry

Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library

Ilane Hernández‐Morales, Peggy Geluykens, Marleen Clynhens, +17

Antiviral Research

MedicineArbovirusAntiviral TherapyVirologyAntiviral Drug +5